Rathmell: We must support our junior colleagues

“Empathy and listening is a key place to start”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Colleagues,

Are you feeling the sting of budget cuts, stalled review panels, and widespread uncertainty in the direction of medicine and biomedical research? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 
W. Kimryn Rathmell, MD, PhD, MMHC
Former director, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login